Navigation Links
Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Date:8/28/2007

SEATTLE, Aug. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that it had received a Deficiency Letter (the "Letter") from Nasdaq indicating that the Company's recently completed registered offering of Series C 3% Convertible Preferred Stock (the "Series C Preferred") and warrants did not comply with voting rights requirements set forth in Nasdaq Marketplace Rule 4351 and IM 4351. The Nasdaq staff verbally notified the Company of such noncompliance on August 9, 2007 and, in response to this verbal notification, the Company took action to cure the deficiency by amending the Articles of Amendment of the Company's Articles of Incorporation, which set forth the rights and preferences of the holders of the Series C Preferred (the "Articles of Amendment"). The amendment to the Articles of Amendment (the "Amendment") adjusted the conversion ratio of the Series C Preferred for purposes of the voting rights provision of the Articles of Amendment, and had the effect of reducing the number of votes that the holders of the Series C Preferred have because it increased the conversion price from $3.90 to $4.53 for purposes of the voting rights provision. The Amendment did not change the conversion price in any other provision of the Articles of Amendment, including but not limited to the provision on conversion of such Series C Preferred into shares of common stock.

The letter confirms that, subject to the public announcement requirements of Nasdaq Marketplace Rule 4803(a), the Company has regained compliance with Nasdaq Marketplace Rule 4351 and IM 4351 and the matter is now closed.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Milwaukee takes another step in electronic patient data exchange
3. Ethics Board site offers welcome contrast to state IT mistakes
4. It takes more than money to reach the top
5. CATI takes tech transfer model national
6. Green economic plan takes cue from Indiana
7. Local software company takes Google to court over a patent
8. American Family CIO takes entrepreneurial approach to innovation
9. TDS takes top spot in region in customer satisfaction rankings
10. Innovative health care takes more than just IT automation
11. Centralization mania takes over
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Middle East & Africa Biomedical Sensors Market - ... offering. The Middle East ... at $0.84 billion by 2018 at a CAGR of ... future will bring Biomedical sensors that are adaptable to ...
(Date:8/31/2015)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... innovative therapies primarily in the areas of dermatology ... period following the filing of the Company,s Investigational ... U.S. Food and Drug Administration (FDA) has passed ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... FRANCISCO, Calif. , Aug. 31, 2015 ... discovery and development of novel cancer immunotherapies, announced today ... Ph.D., as Chief Executive Officer and William Ho ... and Ho join an experienced management team led by ... Jordan Fridman , Ph.D., Chief Scientific Officer; Jay ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... high priority in the drug development approval process. Thus, innovator companies must understand ... Regis Technologies, Inc., a Chicago-based CMO, has been hosting multiple educational panels and ...
Breaking Biology Technology:Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... , Feb. 3 ERT (Nasdaq: ERES ), announced ... full year 2009 on Thursday, February 25, 2010 , after the ... at 5:00 PM EST that day. , For the ... United States or 1-412-858-4600 when calling internationally. There will be a ...
... GENEVA , February 3 Viroblock ... anti-viral products, today,announced that Dr. Jamie Paterson will join ... Jamie Paterson , a British national, can look back at 20 ... was,Chief Commercial Officer at Neurim Pharmaceuticals. During his 18 years at,Procter ...
... Molecular Imaging Summit wrapped up today in Albuquerque, ... energy looking ahead. Nanotechnology is a quickly ... for applying technology in highly targeted ways. For ... target diseaseand treat many common and devastating diseases ...
Cached Biology Technology:ERT to Announce Fourth Quarter and Full Year 2009 Results on February 25, 2010 2Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round 2SNM's nanomedicine summit advances molecular imaging 2SNM's nanomedicine summit advances molecular imaging 3
(Date:8/25/2015)... CITY and BELLEVUE, Wash. ... leader in advanced robotic systems, announced today it will ... unmanned ground vehicle (UGV), at the National Tactical Officers ... The Guardian S is the first-ever ... culmination of years of research and in-field trials and ...
(Date:8/20/2015)... OXFORD, CT ., Aug. 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... wallet, announces it has joined The Smart Card Alliance ... the Smart Card Alliance and the Smart Card Alliance ... and visibility to industry peers and thought leaders promoting ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... School of Medicine have identified a common compound in the ... development of abdominal obesity, insulin resistance, and type 2 diabetes. ... issue of the Proceedings of the National Academy of ... MD, Professor and Director of the Division of Experimental Diabetes ...
... The extreme Texas heat often keeps Houstonians from heading ... however, they,re dissuaded from outdoor activities due to poor ... area can track ozone levels through the Houston Clean ... Houston Endowment, this website ( http://houstoncleanairnetwork.org ) provides real-time ...
... University of Helsinki and the Folkhlsan Research Center ... collaboration with an international group of researchers investigated ... tail chasing in dogs. A questionnaire study covering ... behavior in dogs and humans: early onset, recurrent ...
Cached Biology News:Specific toxic byproduct of heat-processed food may lead to increased body weight and diabetes 2Specific toxic byproduct of heat-processed food may lead to increased body weight and diabetes 3Houston Clean Air Network offering real-time online ozone report 2Canine tail chasing resembles human obsessive compulsive disorders 2Canine tail chasing resembles human obsessive compulsive disorders 3
... Hinge Region By immunoblotting the antibody reacts ... reacts with free MMP-2 or MMP-2 bound ... aqueous glycerol solution Solution in 0.01 ... 50% glycerol and 15 mM sodium azide. ...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z71,381-3) or contact ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Anti-YAP Polyclonal Antibody ... rabbit polyclonal antibody. Detects 70 kDa ... Western blotting and immunohistochemistry. ... Storage: -20C ...
Biology Products: